Results 11 to 20 of about 23,600 (247)

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

BMC Cancer, 2022
Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other ...
Nicole Bourrier, Ivan Landego, Oliver Bucher, Mandy Squires, Erin Streu, Irena Hibbert, Theresa Whiteside, Spencer B. Gibson, Marc Geirnaert, James B. Johnston, David E. Dawe, Versha Banerji   +11 more
doaj   +2 more sources

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn   +15 more
doaj   +2 more sources

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +2 more sources

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance

EMBO Molecular Medicine, 2019
Due to compromised homologous recombination (HR) repair, BRCA1‐ and BRCA2‐mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression.
Eliana MC Tacconi, Sophie Badie, Giuliana De Gregoriis, Timo Reisländer, Xianning Lai, Manuela Porru, Cecilia Folio, John Moore, Arnaud Kopp, Júlia Baguña Torres, Deborah Sneddon, Marcus Green, Simon Dedic, Jonathan W Lee, Ankita Sati Batra, Oscar M Rueda, Alejandra Bruna, Carlo Leonetti, Carlos Caldas, Bart Cornelissen, Laurent Brino, Anderson Ryan, Annamaria Biroccio, Madalena Tarsounas   +23 more
doaj   +2 more sources

Chlorambucil Conjugated Ugi Dendrimers with PAMAM-NH₂ Core and Evaluation of Their Anticancer Activity

Pharmaceutics, 2019
Herein, a new Ugi multicomponent reaction strategy is described to enhance activity and solubility of the chemotherapeutic drug chlorambucil through its conjugation to poly(amidoamine) (PAMAM-NH2) dendrimers with the simultaneous introduction of lipidic (
Nalin Seixas, Bruno B. Ravanello, Ibrahim Morgan, Goran N. Kaluđerović, Ludger A. Wessjohann   +4 more
doaj   +2 more sources

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Leukemia, 2022
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia Jeff P. Sharman 1, Miklos Egyed, Wojciech Jurczak
J. Sharman, M. Egyed, W. Jurczak, A. Skarbnik, J. Pagel, I. Flinn, M. Kamdar, T. Munir, R. Walewska, G. Corbett, L. Fogliatto, Y. Herishanu, V. Banerji, S. Coutre, G. Follows, P. Walker, K. Karlsson, P. Ghia, A. Janssens, F. Cymbalista, J. Woyach, E. Ferrant, W. Wierda, V. Munugalavadla, T. Yu, M. Wang, J. Byrd   +26 more
semanticscholar   +1 more source

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Nature Communications, 2023
Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited.
O. Al-Sawaf, Can Zhang, H. Jin, S. Robrecht, Yoonha Choi, Sandhya Balasubramanian, A. Kotak, Y. Chang, A. Fink, E. Tausch, C. Schneider, M. Ritgen, K. Kreuzer, B. Chyla, Joe Paulson, C. Pallasch, L. Frenzel, M. Peifer, B. Eichhorst, S. Stilgenbauer, Yanwen Jiang, M. Hallek, K. Fischer   +22 more
semanticscholar   +1 more source

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood, 2023
Background: Previous reports of ELEVATE-TN (NCT02475681) at median follow-up of up to 58.2 months (mo) demonstrated superior efficacy of acalabrutinib (A) ± obinutuzumab (O) compared with O + chlorambucil (Clb) in patients (pts) with treatment-naive ...
J. Sharman, M. Egyed, Wojciech Jurczak, A. Skarbnik, K. Patel, I. Flinn, M. Kamdar, T. Munir, R. Walewska, M. Hughes, L. Fogliatto, Y. Herishanu, V. Banerji, G. Follows, Patricia A. Walker, K. Karlsson, P. Ghia, A. Janssens, F. Cymbalista, John C. Byrd, E. Ferrant, A. Ferrajoli, W. Wierda, V. Munugalavadla, Catherine Wangui Wachira, Chuan-Chaun Wun, J. Woyach   +26 more
semanticscholar   +1 more source

Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer. [PDF]

Int J Cancer
What's New? Small cell lung cancer (SCLC) is aggressive and difficult to treat but exhibits high levels of stathmin 1 (STMN1), a candidate therapeutic target. In this study, the authors synthesized a chlorambucil (Chb)‐conjugated pyrrole–imidazole polyamide (PIP) compound targeting the STMN1 promoter and DNA sequences and evaluated its efficacy in ...
Yoshikawa R, Watanabe T, Ohtaki Y, Bando T, Sugiyama H, Araki T, Yashima H, Erkhem-Ochir B, Okami H, Dorjkhorloo G, Shioi I, Nagashima T, Kawatani N, Yazawa T, Narusawa E, Kosaka T, Kawashima O, Kamiyoshihara M, Minna JD, Girard L, Shirabe K, Nagase H, Shimizu K, Yokobori T.   +23 more
europepmc   +2 more sources

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Journal of Clinical Oncology, 2023
PURPOSE In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL).
T. Munir, C. Moreno, C. Owen, G. Follows, O. Benjamini, A. Janssens, M. Levin, A. Osterborg, T. Robak, M. Šimkovič, D. Stevens, Sergey Voloshin, V. Vorobyev, M. Yağcı, L. Ysebaert, K. Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, N. Schuier, K. Baeten, A. Howes, D. B. Caces, C. Niemann, A. Kater   +24 more
semanticscholar   +1 more source